With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.
© 2023 The Abundance Pub. All rights reserved.
All trademarks and service marks are the property of their respective owners. This site is not intended to provide, and does not constitute, medical, health, legal, investment, financial or other professional advice.